An Early Phase 1 interventional study of Insulin Treatment Arm and Control Arm - standard of care in Persistent Corneal Epithelial Defect, sponsored by Massachusetts Eye and Ear Infirmary. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Massachusetts Eye and Ear Infirmary · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn if insulin eye drops, added to standard care, can treat persistent corneal epithelial defects (PEDs) in adults age 18 and older. A PED is a corneal surface wound, at least 2 mm across, that has not healed after more than 14 days of standard treatment such as lubricants, antibiotic drops, or a bandage contact lens. The main question it aims to answer is:
- Does adding insulin eye drops (1 IU/mL, four times daily) to standard care increase the proportion of eyes with complete corneal epithelial healing at 8 weeks?
The standard care plus insulin eye drops will be compared to standard care plus placebo eye drops (preservative-free saline) to see if insulin leads to more complete healing, faster healing, fewer recurrences, and better symptom relief. They will also assess the safety of the drops and their effects on corneal nerves.
Participants will:
Corneal diseases are a leading cause of blindness worldwide according to the World Health Organization; many are in need of a corneal transplant but with a dearth of available tissue and proper medical/surgical expertise and care, the vast majority remain blind. A common cause of corneal blindness is untreated corneal epithelial defects. And as we explain below, the treatment options are very limited.
A persistent corneal epithelial defect (PED) is defined as a failure of the cornea to re-epithelialize within 2 weeks with standard treatment, and is caused by many underlying reasons, including nerve damage (e.g. in diabetes or herpetic infection), trauma, limbal stem cell deficiency, and severe inflammation of the ocular surface, among others. As PEDs are often refractory to conventional therapy (such as lubrication, bandage contact lenses, punctal occlusion, or surgical lid closure), they can progress to serious sequalae such as stromal ulceration, scarring, and even perforation. In particular, corneal scarring is a leading cause of blindness and visual disability, especially in regions with limited access to corneal transplantation. These risks underscore the need for improved and affordable treatments effective in promoting corneal epithelial healing, thereby limiting irreversible scarring and corneal opacity.
Rationale for Topical Insulin Therapy: Insulin is widely known as a metabolic hormone, but it also has growth-factor-like actions in various tissues, including the cornea. Importantly, insulin is widely available worldwide and can easily be compounded into eyedrops for use. The following preliminary evidence supports the use of topical insulin eye drops to promote corneal epithelial defect healing:
Knowledge Gaps and Unmet Need: Despite the scientific rationale and early reports cited above, critical gaps remain in our knowledge that must be addressed before insulin eye drops can be adopted as a standard treatment for corneal healing:
Mechanistic Insights: While insulin's general effects on limbal stem cells are known, the precise mechanisms by which topical insulin promotes corneal epithelial defect closure are still being elucidated. A deeper understanding of the mechanism could help in optimizing combination therapies.
2. Specific Aims and Objectives
The primary objective is to determine whether adjunctive topical insulin (1 IU/mL, four times a day) increases the proportion of PED patients achieving complete corneal healing within 8 weeks, compared to placebo (saline) controls, under double masked conditions.
The secondary objective is to (1) compare time to defect healing vs. without insulin therapy; (2) to assess the durability of healing (rate of recurrence of defects after initial healing); (3) assess patient symptom improvements (pain) with insulin; (4) document safety issues or side effects of topical insulin on the eye; (5) to explore changes in corneal nerve density and sensitivity in insulin-treated eyes.
Massachusetts Eye and Ear Infirmary is the lead sponsor of 101 studies on the registry; 24 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 7 (54%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All control patients will continue to receive standard-of-care (SoC) therapy for PED as determined by the treating cornea specialist. SoC typically may include a preservative-free lubricant regimen, a fluoroquinolone antibiotic drop QID for prophylaxis, and use of a bandage contact lens or eyelid taping if appropriate.
Drug: Control Arm - standard of care
In the insulin arm, patients will receive topical regular human insulin diluted to 1 IU/mL in sterile preservative-free normal saline, applied as an eye drop four times a day (QID).
Drug: Insulin Treatment Arm
The patients will receive topical regular human insulin diluted to 1 IU/mL in sterile preservative-free normal saline, applied as an eye drop four times a day (QID). Additionally, all interventional arm patients will continue to receive standard-of-care (SoC) therapy for PED as determined by the treating cornea specialist. SoC typically may include a preservative-free lubricant regimen, a fluoroquinolone antibiotic drop QID for prophylaxis, and use of a bandage contact lens or eyelid taping if appropriate.
All patients will continue to receive standard-of-care (SoC) therapy for PED as determined by the treating cornea specialist. SoC typically may include a preservative-free lubricant regimen, a fluoroquinolone antibiotic drop QID for prophylaxis, and use of a bandage contact lens or eyelid taping if appropriate.
Complete PED closure rate at 8 Weeks
The primary endpoint is the proportion of eyes in each group that achieve complete corneal epithelial defect closure by 8 weeks of treatment. "Complete healing" is defined as 100% re-epithelialization of the cornea with no fluorescein staining defect remaining, confirmed on two consecutive visits including the final 8-week visit. We will document epithelial closure using fluorescein staining and slit-lamp photography at each follow-up. An independent masked ophthalmologist will review images to confirm healing status, using standardized criteria.
Time frame: 8 weeks
Time to Healing
For each eye that heals during the study, we will record the number of days from treatment initiation to the first visit at which the defect is fully closed. We hypothesize the insulin group will have a faster time-to-healing (accelerated re-epithelialization) compared to controls. We will use survival analysis methods (Kaplan-Meier curves and log-rank test) to compare time-to-healing distributions.
Time frame: 8 weeks
Partial Healing (Defect Reduction)
In eyes that do not completely heal, we will assess the change in defect size. Specifically, the percentage reduction in defect area from baseline to 8 weeks (measured from corneal staining photographs) will be calculated. We will compare the mean reduction and the proportion of eyes achieving at least a 50% reduction in area between groups. This will capture any clinically meaningful improvement short of full closure.
Time frame: 8 weeks
Recurrence Rate
Recurrence is defined as the development of a new corneal epithelial defect greater than 1 mm in diameter at the same anatomical location following documented complete epithelial healing. The outcome will be reported as the percentage of participants who experience at least one recurrence during the 12-week follow-up period after completion of the 8-week treatment phase, among participants whose epithelial defects healed during treatment.
Time frame: From documented complete epithelial healing through 12 weeks after completion of the 8-week treatment period.
Symptom Relief
Ocular surface symptoms and their impact on vision-related functioning will be measured using the validated 12-item Ocular Surface Disease Index (OSDI) questionnaire at baseline and Week 8. The OSDI total score ranges from 0 to 100, with higher scores indicating greater symptom severity and functional impairment. The outcome will be reported as the change in total OSDI score from baseline to Week 8, calculated as the Week 8 score minus the baseline score. Negative values indicate improvement in symptoms.
Time frame: 8 weeks
Safety Outcomes
The number of participants experiencing at least one adverse event during the 8-week treatment period will be recorded and reported for each treatment group. Adverse events will include ocular and systemic events, including ocular surface inflammation, corneal edema, corneal haze, ocular infection, and systemic adverse events potentially associated with treatment. Each participant experiencing one or more adverse events will be counted once for this outcome.
Time frame: 8 weeks
Corneal Sub-Basal Nerve Fiber Density
Corneal sub-basal nerve fiber length density will be quantified using in vivo confocal microscopy (IVCM) at baseline and at all scheduled post-treatment follow-up visits. Nerve fiber length density will be expressed as the total length of visible sub-basal corneal nerve fibers per unit area of corneal tissue (mm/mm²). The outcome will be reported as the change in nerve fiber length density from baseline at each follow-up visit, calculated as the value at the respective follow-up visit minus the baseline value. Positive values indicate an increase in corneal nerve fiber length density.
Time frame: 8 weeks
Corneal Sensitivity
Corneal sensitivity will be measured using a Cochet-Bonnet esthesiometer at baseline and at all scheduled post-treatment follow-up visits. Corneal sensitivity will be quantified as the maximum nylon filament length, expressed in centimeters (cm), that elicits a reproducible corneal sensation or blink response. The outcome will be reported as the change in filament length from baseline at each follow-up visit, calculated as the value at the respective follow-up visit minus the baseline value. Positive values indicate improved corneal sensitivity.
Time frame: 8 weeks
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: The IPD will be available from December 1 till the study is concluded.
Access criteria: The IPD will be available on request from Mr. Michael Cheung, Clinical Research Project Manager.
Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts Eye and Ear Infirmary →